Unknown

Dataset Information

0

Survival after radiation therapy for high-grade glioma.


ABSTRACT: Background:High-grade gliomas (HGGs) are a heterogeneous disease group, with variable prognosis, inevitably causing deterioration of the quality of life. The estimated 2-year overall survival is 20%, despite the best trimodality treatment consisting of surgery, chemotherapy, and radiotherapy. Aim:To evaluate long-term survival outcomes and factors influencing the survival of patients with high-grade gliomas treated with radiotherapy. Materials and methods:Data from 47 patients diagnosed with high-grade gliomas between 2009 and 2014 and treated with three-dimensional radiotherapy (3DRT) or intensity-modulated radiotherapy (IMRT) were analyzed retrospectively. Results:Median survival was 16.6 months; 29 patients (62%) died before the time of analysis. IMRT was employed in 68% of cases. The mean duration of radiotherapy was 56 days, and the mean delay to the start of radiotherapy was 61.7 days (range, 27-123 days). There were no statistically significant effects of duration of radiotherapy or delay to the start of radiotherapy on patient outcomes. Conclusions:Age, total amount of gross resection, histological type, and use of adjuvant temozolomide influenced survival rate (p < 0.05). The estimated overall survival was 18 months (Kaplan-Meier estimator). Our results corroborated those reported in the literature.

SUBMITTER: Marra JS 

PROVIDER: S-EPMC6187089 | biostudies-literature | 2019 Jan-Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Survival after radiation therapy for high-grade glioma.

Marra Joana Spaggiari JS   Mendes Guilherme Paulão GP   Yoshinari Gerson Hiroshi GH   da Silva Guimarães Flávio F   Mazin Suleimy Cristina SC   de Oliveira Harley Francisco HF  

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology 20181011 1


<h4>Background</h4>High-grade gliomas (HGGs) are a heterogeneous disease group, with variable prognosis, inevitably causing deterioration of the quality of life. The estimated 2-year overall survival is 20%, despite the best trimodality treatment consisting of surgery, chemotherapy, and radiotherapy.<h4>Aim</h4>To evaluate long-term survival outcomes and factors influencing the survival of patients with high-grade gliomas treated with radiotherapy.<h4>Materials and methods</h4>Data from 47 patie  ...[more]

Similar Datasets

| S-EPMC8452624 | biostudies-literature
| S-EPMC8797698 | biostudies-literature
| S-EPMC5471301 | biostudies-literature
| S-EPMC9798905 | biostudies-literature
| S-EPMC7016983 | biostudies-literature
| S-EPMC3101937 | biostudies-literature
| S-EPMC4746478 | biostudies-literature
2021-05-27 | GSE175543 | GEO
| S-EPMC7992220 | biostudies-literature
| S-EPMC5716167 | biostudies-literature